Mepolizumab (Nucala®, GlaxoSmithKline) for Asthma

CTAF
February 12, 2016 9:00AM-3:30PM

The California Endowment, Oakland, CA

The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting in February 2016 to discuss a drug for patients with severe eosinophilic asthma. The asthma drug, mepolizumab (Nucala®, GlaxoSmithKline), is a once-monthly injectable monoclonal antibody against interleukin-5 (IL-5).

Key Dates

Associated Materials

10/13/2015

11/19/2015

12/21/2015

12/21/2015

12/21/2015 – 01/12/2016

Public comments received on the Draft Evidence Report.